Wohl & Fruchter LLP

Call Us 866-833-6245

  • About
  • Attorneys
  • Practice Areas
  • Cases
  • Results
  • News
  • Contact
  1. Home
  2. Cases
  3. Rain Oncology

Rain Oncology

We are investigating the fairness of the $1.16 per share in cash, plus a contingent value right (“CVR”) for up to $0.17 per share in cash, at which Rain Oncology, Inc. (Nasdaq: RAIN) (“RAIN”) has agreed to be sold to Pathos AI, Inc. (“Pathos”) via a tender offer.

If you remain a RAIN shareholder and question the fairness of the price, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.

Why is there an investigation?
On December 13, 2023, RAIN announced that it had agreed to be sold to Pathos via a tender offer at a price of $1.16 per share of in cash, plus a CVR for up to $0.17 per share in cash upon achievement of certain cash balance and clinical milestones.

“We are investigating whether the RAIN Board of Directors acted in the best interests of RAIN shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes the terms of the CVR, including the probability that the milestones will be achieved within the timelines specified.”

Notably, the deal price is well below RAIN’s 52-week high of $14.48 per share, which indicates the transaction may be opportunistic to take advantage of RAIN’s setback earlier this year when it announced that its lead product candidate, milademetan, did not reach the primary endpoint in a Phase 3 trial for patients with liposarcoma, a rare type of cancer.

Contact Us About This Case

"*" indicates required fields

If you lost money, enter $ amount, and hit "tab" to verify. If you have a gain, enter $0.
Please check box*
This field is hidden when viewing the form
This field is for validation purposes and should be left unchanged.
Click to Contact Us About This Case

Attorney

Joshua Fruchter
845-290-6818
alerts@wohlfruchter.com

  • Legal
  • Privacy Policy
  • Sitemap
  • Contact

Attorney Advertising. Prior results do not guarantee a similar outcome.

© 2025 Wohl & Fruchter LLP